Core Viewpoint - The announcement details a change in the equity stake of the controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., in Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd., indicating a decrease in ownership percentage from 61.56% to 60.85% due to the repurchase and cancellation of restricted shares [1][2]. Group 1 - The controlling shareholder's equity stake decreased from 61.56% to 60.85% [1][2]. - The change in equity does not trigger mandatory tender offer obligations [1]. - The equity change is attributed to the repurchase and cancellation of restricted shares, which affected the total share capital of the company [2]. Group 2 - Heilongjiang Chuangda Group's shareholding decreased from 579,885,300 shares to 572,558,277 shares [1][2]. - The equity change occurred during the period of October 12, 2023, to December 8, 2023 [1]. - The company assures that the change in shareholding will not affect the status of the controlling shareholder or actual controller [2].